You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • AB0880 Pharmacodynamic effects and safety of verinurad (RDEA3170) in combination with allopurinol versus allopurinol alone in adults with gout: a phase 2a, open-label study

Article metrics

Article menu

Download PDFPDF

Abstracts Accepted for Publication
Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis
AB0880 Pharmacodynamic effects and safety of verinurad (RDEA3170) in combination with allopurinol versus allopurinol alone in adults with gout: a phase 2a, open-label study
Free

 

Online download statistics by month:

Online download statistics by month: June 2017 to March 2024

AbstractFullPdf
Jun 20171202
Jul 2017800
Aug 20171600
Sep 20172200
Oct 20171004
Nov 20172802
Dec 20172002
Jan 20184203
Feb 20181700
Mar 20184001
Apr 20184000
May 20181601
Jun 20181000
Jul 20181800
Aug 20183201
Sep 20181602
Oct 20181005
Nov 2018407
Dec 2018801
Jan 20191802
Feb 2019802
Mar 2019903
Apr 20191004
May 2019903
Jun 2019902
Jul 2019502
Aug 20191402
Sep 2019201
Oct 20191403
Nov 2019704
Dec 2019601
Jan 2020601
Feb 2020505
Mar 2020001
Apr 2020200
May 2020002
Jun 2020403
Jul 20201601
Aug 20201205
Sep 20201402
Oct 2020802
Nov 2020204
Dec 2020800
Jan 2021606
Feb 2021201
Mar 2021001
Apr 2021905
May 2021003
Jun 2021002
Jul 2021100
Aug 2021004
Sep 2021103
Oct 202113021
Nov 20219011
Dec 20211403
Jan 2022200
Feb 20222202
Mar 2022404
Apr 20221502
May 20222807
Jun 20221802
Jul 2022701
Aug 20222808
Sep 2022403
Oct 2022804
Nov 2022601
Dec 2022601
Jan 20231402
Feb 2023400
Mar 20235802
Apr 2023402
May 2023403
Jun 2023200
Jul 2023303
Sep 2023401
Oct 2023400
Nov 2023700
Dec 20231400
Jan 2024401
Feb 2024602
Mar 20241601
Total9040198